XenoPort to Release Fourth Quarter and Year-End Financial Results on February 25, 2016
February 16 2016 - 10:00AM
Business Wire
XenoPort, Inc. (NASDAQ:XNPT) announced today that it will
release its fourth quarter and year-end financial results on
February 25, 2016 at approximately 4:30 p.m. Eastern Time. The
company will host a conference call at 5:00 p.m. Eastern Time that
same day to provide a summary of its financial results and general
business updates. A replay of the call will be available for one
week following the event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial
1-888-275-3514. International callers may access the live call by
dialing 706-679-1417. The reference number to enter the call is
77034895.
The replay of the conference call may be accessed that same day
after 8:00 p.m. Eastern Time, via the Internet, at
www.XenoPort.com, or via phone at 1-855-859-2056 for domestic
callers, or 404-537-3406 for international callers. The reference
number to enter the replay of the call is 51661251.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
commercializing HORIZANT® (gabapentin enacarbil) Extended-Release
Tablets in the United States. XenoPort has entered into a clinical
trial agreement with the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) under which the NIAAA has initiated a clinical
trial evaluating gabapentin enacarbil as a potential treatment for
patients with alcohol use disorder. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort has granted exclusive world-wide rights for
the development and commercialization of its clinical-stage oral
product candidate, arbaclofen placarbil, to Indivior PLC for all
indications. XenoPort’s other product candidates include XP23829, a
novel fumaric acid ester prodrug that is a potential treatment for
patients with moderate-to-severe chronic plaque-type psoriasis or
patients with relapsing forms of multiple sclerosis, and XP21279, a
prodrug of levodopa that is a potential treatment for patients with
idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the Website at
www.XenoPort.com.
XENOPORT, HORIZANT and REGNITE are registered trademarks of
XenoPort, Inc.
XNPT2F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160216005279/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7295ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024